isu302
Gaucher Disease
ISU Abxis Co., Ltd.Phase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Gaucher Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Taliglucerase Alfa Protalix | Phase 4 | A |
Velaglucerase Alfa Takeda | Phase 4 | A |
Cerezyme Sanofi | Phase 4 | A |
Cerezyme Sanofi | Phase 4 | BBB |
Eliglustat Peking Union Medical College Hospital | Phase 3 | BBB |
View all 30 →
Same molecule, other indications
isu302 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →